Targeted therapy for breast cancer

doi:10.3877/cma.j.issn.1674-0807.2021.06.001

Abstract

Abstract:

Targeted therapy is a treatment mode with low toxicity and high selectivity. Trastuzumab, as one of the "classic" drugs in the history of targeted therapy for breast cancer, has benefited thousands of breast cancer patients. With the continuous exploration on the mechanism of tumorigenesis, development and metastasis, breakthroughs have been made in the research and application of targeted drugs, which provides a new therapeutic strategy for the improvement of patient survival. In this paper, we summarized the research progress of potential targets and targeted drugs for breast cancer patients.

Key words: Breast neoplasms, Molecular targeted therapy, Drug therapy

Zhantao Liu, Yanqiu Song. Targeted therapy for breast cancer[J]. Chinese Journal of Breast Disease(Electronic Edition), 2021, 15(06): 329-336.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2021.06.001

https://zhrxbzz.cma-cmc.com.cn/EN/Y2021/V15/I06/329

References 56

[1]	Chen W, Zheng R, Baade PD，et al.Cancer statistics in China，2015 [J]．CA Cancer J Clin，2016，66(2)：115-132.
[2]	李依敏，苏思贞，朱静，等．乳腺癌靶向治疗药物治疗研究进展 [J]．山东医药，2017，57(9)：107-109.
[3]	中国抗癌协会乳腺癌专业委员会．Her-2阳性乳腺癌临床诊疗专家共识 [J]．中国癌症杂志，2012，22(4)：314-318.
[4]	江泽飞，邵志敏，徐兵河．人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识2016 [J]．中华医学杂志，2016，96(14)：1091-1096.
[5]	Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017 [J]. Ann Oncol, 2017, 28(8): 1700-1712.
[6]	U．S.Food and Drug Administration.FDA grants regular approval to pertuzumab for adjuvant treatment of HER2-positive breast cancer[EB/OL]．[2019-07-01]. URL
[7]	Gianni L, Pienkowski T, Im YH，et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER-2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial [J]. Lancet Oncol, 2016, 17(6): 791-800.
[8]	von Minckwitz G, Procter M, de Azambuja E，et al.Adjuvant pertuzumab and trastuzumab in eraly HER-2-positive breast cancer [J]．N Engl J Med，2017，377(2)：122-131.
[9]	Swain SM, Baselga J, Kim SB，et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer [J]．N Engl J Med, 2015, 372(8): 724-734.
[10]	Loi S,，Giobbe-Hurder A,，Gombos A，et al. PhaseⅠb/Ⅱstudy evaluating the efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER-2-positive metastatic breast cancer：Results from the PANACEA (IBCSG45-13/KEYNOTE-014) study[EB/OL]．[2019-06-01]. URL
[11]	Rugo HS, Im SA, Cardoso F，et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2 positive advanced breast cancer: a phase 3 randomized clinical trial[J]. JAMA Oncol，2021，7(4)：573584.
[12]	vonMinckwitz G, Huang CS, Mano MS，et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer [J]．N Engl J Med，2019，380(7)：617-628.
[13]	Sakai H, Tsurutani J, Iwasa T, et al.HER-2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER-2-positive metastatic breast cancer [J]．Breast Cancer，2018，25(5): 605-613.
[14]	Hongbin W, Wenqin W, Yanping X，et al.Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells [J]．Cancer Sci，2017，108(7)：1458-1468.
[15]	U．S.Food and Drug Administration.FDA approves new treatment to reduce the risk of breast cancer returning [EB/OL]．[2019-07-01]． URL
[16]	Chan A, Delaloge S, Holmes FA，te al.Neratinib after trastuzumab-based adjuvant therapy in patients with HER-2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled，phase 3 trial [J]. Lancet Oncol, 2016, 17(3): 367-377.
[17]	Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER-2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebocontrolled, phase 3 trial [J]. Lancet Oncol, 2017, 18(12): 1688-1700.
[18]	Fei Ma, Quchang Ouyang, Wei Li，et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase Ⅱ study [J]．J Clin Oncol，2019，37(29)：2610-2619.
[19]	Xu B, Yan M, Ma F，et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial [J]. Lancet Oncol，2021，22(3)：351-360.
[20]	Zhou Z, Qiao JX, Shetty A，et al. Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy [J]．Cell Mol Life Sci，2014，71(8)：1549.
[21]	金科，赵丹，杨林，等．CDK4/6抑制剂联合内分泌治疗对乳腺癌细胞miRNA表达水平的影响 [J]. 现代肿瘤医学，2019，27(5)：723-727.
[22]	国家药品监督管理局.2018年审评通过的优先审评药品名单[EB/OL]．[2019-07-01]. URL
[23]	Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first line therapy for HR-positive, advanced breast cancer [J]. N Engl J Med, 2016, 375(18)：1738-1748.
[24]	Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormonereceptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial [J]. Lancet Oncol, 2018, 19(7)：904-915.
[25]	Slamon DJ, Neven P, Chia S，et al.Phase Ⅲ randomized study of ribociclib and Fulvestrant in hormone receptor-positive，human epidermal growth factor receptor 2-negative advanced breast cancer：MONALEESA-3 [J]．J Clin Oncol，2018，36(24)：2465-2472.
[26]	Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer [J]. N Engl J Med，2019，381(4)：307-316.
[27]	O’Leary B, Cutts RJ, Liu Y, et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial[J]. Cancer Discov, 2018，8(11)：1390-1403.
[28]	Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer [J]．N Engl J Med，2015，373(3)：209-219.
[29]	Hares SH, Harvey AJ. mTOR function and therapeutic targeting in breast cancer [J]．Am J Cancer Res，2017，7(3)：383-404.
[30]	Paplomata E, O’Regan R．The PI3K/AKT/mTOR pathway in breast cancer：targets，trials and biomarkers [J]．Ther Adv Med Oncol，2014，6(4)：154-166.
[31]	Tesch H, Stoetzer O, Decker T，et al.Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase ⅢB 4EVER trial [J]．Int J Cancer，2019，144(4)：877-885.
[32]	Jones RH, Casbard A, Carucci M，et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial[J]. Lancet Oncol，2020，21(3)：345-357.
[33]	Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry[J]. Cancer，2007，109(9)：1721-1728.
[34]	国家药品监督管理局．首个国产PD-1抗体药物特瑞普利单抗注射液获批上市 [EB/OL]．[2018-12-17]． URL
[35]	黄述斌，侯永微，李松梅，等．乳腺癌组织及间质浸润淋巴细胞中PD-L1的表达及其意义 [J]．临床与实验病理学杂志，2017，33(1)：63-67.
[36]	Cimino-Mathews A, Thompson E, Taube J M，et a1.PD-L1(B7-H1 ) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas [J]．Human Pathol，2016，47(1)：52-63.
[37]	Nanda R, Specht J, Dees C，et al.KEYNOTE-012：long-lasting response in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC) [J]. Cancer Res，2017, 77(4 Suppl)：P6-10-03.
[38]	Adams S, Loi S, Toppmeyer D, et at. Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC)：preliminary data from KEYNOTE-086 cohort B [J]．J Clin Oncol，2017，35(15 Suppl)：1088.
[39]	Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer [J]. N Engl J Med，2018，379(22)：2108-2121.
[40]	Schmid P, Rhgo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion 130): updated efficacy, from a randomised，double-blind placebo-controlled，phase 3 trial [J]. Lancet Oncol, 2020, 21(1): 44-59.
[41]	Schmid P, Adams S, Rugo HS，et al.Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer [J]．N Eng J Med，2018，379(22)：2108-2121.
[42]	U．S. Food and Drug Administration. FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer[EB/OL]．[2019-03-08]． URL
[43]	Sikov WM, Berry DA, Perou CM，et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triple-negative breast cancer: CALGB 40603 (Alliance) [J]. J Clin Oncol，2015，33(1)：13-21.
[44]	Symonds L, Linden H, Gadi V，et al.Combined targeted therapies for first-line treatment of metastatic triple negative breast cancer-a phase Ⅱ trial of weekly nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib [J]．Clin Breast Cancer，2019，19(2)：e283-e296.
[45]	Tian S, Quan H, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo[J]. Cancer Sci，2011，102(7)：1374-1380.
[46]	鲁凯莉．阿帕替尼治疗晚期难治性三阴性乳腺癌的临床疗效探讨 [J]．中国处方药，2018，16(6)：75-76.
[47]	Li YH, Zhou Y, Wang YW，et al.Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study [J]．Medicine (Baltimore)，2018，97 (36)：e12222.
[48]	Lee LJ, Alexander B, Schnitt SJ，et al.Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers [J]．Cancer，2011，117( 14): 3093-3100.
[49]	Hu T, Liu C, Li Q，et al. Tapatinib + CPT-11 + S-1 for treatment of refractory brain metastases in patient with triple-negative breast cancer：Case report and literature review [J]．Medicine (Baltimore), 2018, 97(15)：e0349.
[50]	Li T, Wang SB, Lei KJ，et al. Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer：A case report [J]．Medicine (Baltimore)，2019，98(4)：e14182.
[51]	张秀伟，钟文，魏士博，等．三阴性乳腺癌与PARP1表达相关性的Meta分析 [J]．现代肿瘤医学，2017，25(6)：893-896.
[52]	Vinayak S, Tolaney SM, Schwartzberg L，et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer[J]. JAMA Oncol，2019，5(8)：1132-1140.
[53]	Pietri E, Conteduca V, Andreis D, et al. Androgen receptor signaling pathways as a target for breast cancer treatment [J]. Endocr Relat Cancer，2016，23(10)：R485-498.
[54]	Lyons T, Gucalp A, Arumov A, et al. Safety and tolerability of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer[J]. J Clin Oncol，2018，36(15 suppl)：531.
[55]	Traina TA, Miller K, Yardley DA, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer [J]. J Clin Oncol, 2018，36(9)：884-890.
[56]	Schmid P, Abraham J, Chan S, et al. AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase Ⅱ trial[J]. J Clin Oncol，2018，36(15 suppl)：1007.

Please choose a citation manager

Content to export